• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Severance for those that "Evolve"

To do nothing for those that "evolve" will kill whatever spirit is left in those that are left behind. It will be a clear example of how much there company demonstrates HHC to its own employees. Once again, Eisai's short sighted strategy to save a buck will cost them going forward. Good luck to everyone.

No offense, but do you get the impression that anybody cares how much "spirit" is left? They hope that just the relief of still having a job for a little while can do the trick. If not you'll just have to force yourself to appear motivated.
 




Similar threads

Replies
1
Views
649
Eisai
Anonymous
Replies
0
Views
447
Eisai
Anonymous
Replies
10
Views
1K
Eisai
Anonymous
Replies
15
Views
5K
Eisai
Anonymous